Karim Rihawi

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Cancer of unknown primary genomic profiling from cell-free DNA provides insights into CUP biology and vulnerabilities.

Cancer of unknown primary genomic profiling from cell-free DNA provides insights into CUP biology and vulnerabilities.

Journal: Frontiers in medicine

Published: December 29, 2025

Complete locoregional response to radiotherapy and pembrolizumab in an elderly and frail patient with oropharyngeal squamous cell carcinoma: A case report.

Complete locoregional response to radiotherapy and pembrolizumab in an elderly and frail patient with oropharyngeal squamous cell carcinoma: A case report.

Journal: Medicine

Published: May 19, 2025

Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.

Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.

Journal: Journal for immunotherapy of cancer

Published: April 18, 2025

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: June 13, 2024

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 05, 2023

Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.

Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.

Journal: Anti-cancer drugs

Published: March 24, 2022

Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer.

Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer.

Journal: Cancers

Published: March 01, 2022

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.

Journal: ESMO open

Published: February 13, 2022

A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.

A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.

Journal: Future oncology (London, England)

Published: January 24, 2022

Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: a case series.

Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: a case series.

Journal: Acta gastro-enterologica Belgica

Published: October 02, 2021

The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer.

The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 21, 2021

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?

Journal: Cancers

Published: March 14, 2021

Showing 1-12 of 50

Last Updated: 09/26/2026